Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer

Cancer Cytopathology

Volumn 117, Issue 1, 2009, Pages 32-39

  Uzan, Catherine ^a   Andre, Fabrice ^a   Scott, Veronique ^a   Laurent, Isabelle ^a   Azria, Elie ^b   Suciu, Voichita ^a   Balleyguier, Corinne ^a   Lacroix, Ludovic ^a   Delaloge, Suzette ^a   Vielh, Philippe ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Breast cancer; Estrogen receptor; Fine needle aspiration cytology; Gene expression; HER 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA;

ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; MIDDLE AGED; NEEDLE BIOPSY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 65349180301     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20008     Document Type: Article

References (16)

1. Schmitt FC, Longatto-Filho A, Valent A, Vielh P. Molecular techniques in cytopathology practice. J Clin Pathol. 2008;61:258-267.
2. Farshid G, Downey P, Gill PG, Pieterse S. Assessment of 1183 screen-detected, category 3B, circumscribed masses by cytology and core biopsy with long-term follow-up data. Br J Cancer. 2008;98:1182-1190.
3. Bergqvist J, Ohd JF, Smeds J, et al. Quantitative real-time PCR analysis and microarray-based RNA expression of HER-2 in relation to outcome. Ann Oncol. 2007;18:845-850.
4. Hamill J, Campbell ID, Mayall F, Bartlett AS, Darlington A. Improved breast cytology results with near patient FNA diagnosis. Acta Cytol. 2002;46:19-24.
5. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 2001;357:1335-1336.
6. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res. 2006; 12:3306-3310.
7. Jeronimo CP, Monteiro P, Henrique R, et al. Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Res Treat. 2008;109:27-34.
8. Klijanienko J, Couturier J, Galut M, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer (Cancer Cytopathol). 1999;87:312-318.
9. Lacroix M, Querton G, Hennebert P, et al. Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immunocytochemical assay, and Northern blot: a comparison. Breast Cancer Res Treat. 2001;67:263-271.
10. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
11. Pusztai L, Ayers M, Stec J, et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal largescale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003;9:2406-2415.
12. Gong Y, Yan K, Lin F, et al. Determination of oestrogenreceptor status and ERBB2 status of breast carcinoma: a geneexpression profiling study. Lancet Oncol. 2007;8:203-211.
13. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003;97:2960-2971.
14. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
15. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER-2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002; 94:855-857.
16. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581.